Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Receivables (2016 - 2024)

Historic Change in Receivables for Gyre Therapeutics (GYRE) over the last 11 years, with Q4 2024 value amounting to $1.1 million.

  • Gyre Therapeutics' Change in Receivables rose 17717.17% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$339000.0, marking a year-over-year increase of 8345.53%. This contributed to the annual value of $5.3 million for FY2024, which is 194456.14% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Change in Receivables of $1.1 million as of Q4 2024, which was up 17717.17% from -$1.5 million recorded in Q4 2023.
  • Gyre Therapeutics' Change in Receivables' 5-year high stood at $1.8 million during Q4 2020, with a 5-year trough of -$13.6 million in Q1 2020.
  • Moreover, its 5-year median value for Change in Receivables was -$498500.0 (2020), whereas its average is -$1.3 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 15844.56% in 2022, then skyrocketed by 17717.17% in 2024.
  • Gyre Therapeutics' Change in Receivables (Quarter) stood at $1.8 million in 2020, then plummeted by 59.95% to $704000.0 in 2021, then crashed by 180.11% to -$564000.0 in 2022, then plummeted by 163.3% to -$1.5 million in 2023, then skyrocketed by 177.17% to $1.1 million in 2024.
  • Its Change in Receivables stands at $1.1 million for Q4 2024, versus -$1.5 million for Q4 2023 and -$564000.0 for Q2 2022.